Genmab Geared Up To Launch Epkinly With AbbVie
As FDA Approves CD20xCD3 Bispecific For Lymphoma
The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.
